Yahoo Finance • 23 days ago
Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutiv... Full story
Yahoo Finance • 24 days ago
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that St... Full story
Yahoo Finance • last month
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (... Full story
Yahoo Finance • 2 months ago
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its p... Full story
Yahoo Finance • 2 months ago
- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 the... Full story
Yahoo Finance • 2 months ago
HUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced th... Full story
Yahoo Finance • 3 months ago
Serina Therapeutics, Inc. (NASDAQ:SER), a $53.7 million market cap biotech company, saw its Chief Scientific Officer Randall Moreadith sell 6,500 shares of common stock on July 14, 2025, for a total of $32,565. The shares were sold at pric... Full story
Yahoo Finance • 3 months ago
How Parkinson’s affects million “ and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s careSerina’s drug candidate SER-252 is designed to deliver continuous symptom reliefJo... Full story